insights_auto
Why is ABVX down 2,02%?
Dive Deeperchevron_right
ABVX:EPA
Abivax SA
82,65 €
arrow_downward
-2,02%(-1,70) 1D
22-окт., 13:55:54 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
81,50 €
High
83,10 €
Low
81,35 €
Mkt. cap
7,24 млд
Avg. vol.
121,63 миң
Volume
17,44 миң
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
Open
81,50 €
High
83,10 €
Low
81,35 €
Mkt. cap
7,24 млд
Avg. vol.
121,63 миң
Volume
17,44 миң
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
News stories
From web sources and news partners
FinancialContent
·
21 мүнөт мурун
Blackstone (NYSE:BX) misses Q3 2026 revenue estimates
StreetInsider
·
14 мүнөт мурун
FORT Robotics raises $20M led by Tiger Global ahead of Nasdaq listing
TradingView
·
1 саат мурун
Tractor Supply’s (NASDAQ:TSCO) Q3 2026 sales top estimates
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded2013-ж., 4-дек.
Headquarters-
Sector-
Websiteabivax.com